6CL-ADBA cannabinoid
6CL-ADBA cannabinoid
6-CL-ADBA for sale is a potent research chemical belonging to the synthetic cannabinoid family. The IUPAC name for 6-CL-ADBA is 6-chloro-1-(4-fluorobenzyl)-N-(2-methylpropan-2-yl)-1H-indazole-3-carboxamide, and its CAS number is 1364933-55-0. This compound is highly sought after by researchers studying the effects of synthetic cannabinoids on the brain and behavior due to its potent and unique properties.
What is 6CL-ADBA cannabinoid ?
The three types of cannabinoids that people use are recreational, medicinal and synthetic.
Research has found that the cannabis plant produces between 80 and 100 cannabinoids and about 300 non-cannabinoid chemicals.1 The two main cannabinoids are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
The most commonly known of the two is delta-9-tetrahydrocannabinol (THC), which is the chemical that is responsible for the psychoactive effects of cannabis.2
The main difference between the two cannabinoids is that THC has strong psychoactive effects, meaning it makes a person ‘high’, whereas CBD is thought to have an anti-psychoactive effect that controls or moderates the ‘high’ caused by the THC. CBD is also thought to reduce some of the other negative effects that people can experience from THC, such as anxiety.3
Commonly used cannabinoids
- Butane hash oil
- Cannabidiol
- Cannabis
- Medicinal cannabis
- Synthetic cannabinoids
What do cannabinoids do?
Similar to opioids, 6-CL-ADBA for sale cannabinoids produce their effects by interacting with specific receptors, located within different parts of the central nervous system. Simply put, cannabinoids regulate how cells communicate—how they send, receive, or process messages.
Types of cannabinoids
- Cannabis – the dried leaves and flowers (buds) of the cannabis plant that are smoked in a joint or a bong. This is the most common form.
- Hemp – the fibre of the cannabis plant, extracted from the stem and used to make rope, strong fabrics, fibreboard and paper.
- Medicinal cannabinoids including pharmaceutical cannabis products that are approved by the Therapeutic Goods Administration (TGA), including nabiximols (Sativex) and synthetic cannabinoids such as Dronabinol.
- HU-210 – a synthetic analogue of THC, first synthesised in Israel in 1988 and considered to have a potency of at least 100 times that of THC. 6
- UR-144 – similar effects to THC, though slightly less potent than THC.7
- JWH – a series of synthetic cannabinoids created in 1994 by Dr John W. Huffman for studies of the cannabinoid receptors.8
- 5F-ADB – a synthetic cannabinoid that was first identified in late 2014 from post-mortem samples taken from an individual who had died after using a product containing this substance.8
- CUMYL-PEGACLONE emerged in late 2016 on the German drug market.9 Anecdotal reports suggest that there are a number of adverse effects associated with CUML-PEGACLONE.
Showing the single result